此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交易商、銀行經理、 律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下全部浙江同源康醫藥股份有限公司之股份，應立即將本通函及隨附代表委任表格送交買方或 承讓人，或送交經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不會就因本通函全部或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） (1) 建議修訂組織章程細則； (2) 建議撤銷監事會； (3) 建議修訂董事會議事規則； (4) 建議修訂股東會議事規則； (5) 建議採納2025年H股激勵計劃；及 (6) 2025年第二次臨時股東大會通告 本封面頁所用詞彙具有本通函所界定的相同涵義。 董事會函件載於本通函第4至8頁。 本公司謹訂於2025年10月30日（星期四）下 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 1 建議採納2025年H股激勵計劃 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 建議修訂組織章程細則； 建議撤銷監事會； 建議修訂董事會議事規則； 建議修訂股東會議事規則；及 建議採納2025年H股激勵計劃 本公告由浙江同源康醫藥股份有限公司（「本公司」）根據香港聯合交易所有限公司 證券上市規則（「上市規則」）第13.51(1)條作出，內容有關建議修訂本公司之組織 章程細則（「組織章程細則」）及建議採納本公司之2025年H股激勵計劃（「2025年H 股激勵計劃」）。 建議修訂組織章程細則及建議撤銷監事會 本公司董事會（「董事會」）謹此建議對組織章程細則作出若干修訂（「建議修訂章程 細則」），以革新組織架構、加強維護本公司中小股東（「股東」）權益、撤銷本公司 監事會（「監事會」）及訂明董事會審計委員會須根據於2024年 ...

為符合資格出席臨時股東大會並於會上投票，所有過戶文件連同相關股票須於 2025年10月23日（星期四）下午四時三十分前，送交本公司的香港H股股份過戶登 記處香港中央證券登記有限公司（地址為香港灣仔皇后大道東183號合和中心17樓 1712-1716號舖）（就本公司H股股東而言），或本公司的中國辦事處（地址為中國 上海市徐匯區龍蘭路277號東航濱江中心T2幢8樓）（就本公司非上市股份股東而 言）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 臨時股東大會之暫停辦理過戶期間 茲提述浙江同源康醫藥股份有限公司（「本公司」）日期為2025年8月31日的公告 （「該公告」），內容有關（其中包括）建議修訂本公司組織章程細則。 董事會謹此宣佈，為釐定本公司股東出席本公司建議臨時股東大會（「臨時股東大 會」）並於會上投票的權利，本公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 本月底法定/註冊股本總額： RMB 380,065,818 備註： 第 1 頁 共 11 頁 v 1.1.1 FF301 FF301 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概念不適用於本公司，上述資料是指本公司的「法定股本」。 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02410 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 375,457,818 | RM ...

Core Insights - The company, Samegene Pharmaceutical, has gained significant attention for its clinical trial results of Eltotinib (TY-9591) for brain metastases in non-small cell lung cancer, presented at the World Lung Cancer Conference in September 2025 [1][2] - The rapid growth of Samegene Pharmaceutical is attributed to its strong R&D pipeline, which includes multiple innovative oncology drugs [1] - The founder, Dr. Wu Yusheng, has over 25 years of experience in biopharmaceutical research and management, previously serving as a senior researcher at Bristol-Myers Squibb [1] Group 1: Eltotinib (TY-9591) Development - Eltotinib is a highly selective small molecule inhibitor targeting EGFR mutations, aimed at addressing treatment challenges for brain metastases in lung cancer patients [2][3] - The Phase II clinical trial for Eltotinib has shown a significant objective response rate (iORR) of 92.8% compared to 76.1% for Osimertinib, with a statistically significant difference (P<0.001) [3] - The company plans to submit a pre-NDA application in April 2025, with conditional approval expected by Q4 2025 [2] Group 2: Clinical Trials and Market Potential - The incidence of brain metastases in lung cancer patients is notably high, with rates of 25%-44% in newly diagnosed advanced lung cancer patients [4] - Eltotinib is positioned to meet the urgent clinical needs of patients with brain metastases, as there are currently no approved third-generation EGFR-TKIs for this indication [4] - The sales of third-generation EGFR-TKIs in China have exceeded 10 billion yuan [4] Group 3: Other Pipeline Developments - Samegene Pharmaceutical is developing TY-0540, a new generation oral CDK2/4 inhibitor, which has received clinical approval for trials in breast and prostate cancer [5][6] - Initial Phase I trial results for TY-0540 indicate promising efficacy in treating CDK4/6 resistant HR+/HER2- breast cancer and platinum-resistant ovarian cancer [6] - The company is also advancing TY-2699a, a CDK7 inhibitor, which has shown good safety and preliminary efficacy in treating triple-negative breast cancer [7][8]

Core Insights - The article highlights significant changes in the stock holdings of various companies in the Hong Kong Stock Connect, with notable increases and decreases in ownership percentages [1][2]. Group 1: Companies with Increased Holdings - Yihua Tong (02402) saw the largest increase in stock holdings, rising by 14.82% to a total holding of 24.14% [2]. - Hong Kong Broadband (01310) experienced a 4.71% increase, bringing its holding to 4.99% [2]. - Dongfang Electric (01072) had a 2.17% increase, resulting in a holding of 39.16% [2]. - Other companies with notable increases include Beijing Machinery (00187) (+1.99%, 53.15%), and East Jiang Environmental Protection (00895) (+1.69%, 43.93%) [2]. Group 2: Companies with Decreased Holdings - Longpan Technology (02465) faced the largest decrease, with a drop of 3.69% to a holding of 47.77% [2]. - Shandong Molong (00568) saw a decrease of 1.44%, resulting in a holding of 53.78% [2]. - Da Zhong Public Utilities (01635) decreased by 1.39%, with a holding of 33.57% [2]. - Other companies with significant decreases include Huahong Semiconductor (01347) (-1.16%, 23.26%) and Jintian Copper (-1.10%, 24.66%) [2]. Group 3: Five-Day Changes in Holdings - Over the last five trading days, Yihua Tong (02402) had the highest increase of 14.99%, maintaining a holding of 24.14% [3]. - Tongyuan Kang Pharmaceutical-B (02410) increased by 7.60%, reaching a holding of 24.20% [3]. - Changfei Optical Fiber (06869) rose by 7.41%, with a holding of 69.80% [3]. - Companies with notable decreases include Shandong Molong (00568) (-3.89%, 53.78%) and Baiguoyuan Group (02411) (-3.55%, 9.28%) [3]. Group 4: Twenty-Day Changes in Holdings - In the last twenty days, Yihua Tong (02402) increased by 14.87%, holding at 24.14% [4]. - Changfei Optical Fiber (06869) saw a rise of 13.73%, maintaining a holding of 69.80% [4]. - Zhongyuan Marine Energy (01138) increased by 12.27%, with a holding of 68.92% [4].

Core Viewpoint - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies, which may signal investment trends and market sentiment. Group 1: Companies with Increased Holdings - Changfei Fiber Optics (06869) saw the largest increase in holdings, up by 5.51%, bringing the total to 68.51% [1][2] - Tongyuan Kang Pharmaceutical-B (02410) increased by 2.18%, with a new holding percentage of 23.40% [1][2] - Fortior Technology (Shenzhen) Co., Ltd. (01304) experienced a 2.14% increase, resulting in a holding of 14.00% [1][2] - Other notable increases include Tianyue Advanced (02631) at +1.85% (13.18%) and Kanglong Chemical (03759) at +1.48% (62.37%) [2] Group 2: Companies with Decreased Holdings - Southern Hengsheng Technology (03033) had the largest decrease, down by 1.10% to 60.60% [1][2] - Haotian International Construction Investment (01341) decreased by 0.90%, now at 60.82% [1][2] - Beijing Beichen Industrial Holdings (00588) saw a reduction of 0.76%, bringing its holding to 39.85% [1][2] - Other significant decreases include Hongye Futures (03678) at -0.74% (63.01%) and Yisou Technology (02550) at -0.73% (35.50%) [2] Group 3: Five-Day Holding Changes - Over the last five trading days, Tongyuan Kang Pharmaceutical-B (02410) had the highest increase at +6.99%, with a holding of 23.40% [1][3] - Changfei Fiber Optics (06869) increased by 5.91%, reaching 68.51% [1][3] - Longpan Technology (02465) saw a 5.41% increase, now at 51.46% [1][3] - Conversely, Shandong Molong (00568) experienced the largest decrease at -4.44%, with a holding of 55.22% [1][3] Group 4: Twenty-Day Holding Changes - In the last twenty days, Zhongyuan Marine Energy (01138) had the highest increase at +12.54%, with a holding of 69.07% [1][4] - Changfei Fiber Optics (06869) also saw a significant increase of +12.33%, now at 68.51% [1][4] - Tongyuan Kang Pharmaceutical-B (02410) increased by +8.83%, reaching 23.40% [1][4]

浙江同源康醫藥股份有限公司 TYK Medicines, Inc 股份代號 : 2410 2025 中期報告 浙江同源康醫藥股份有限公司 目錄 公司資料 董事 2 公司資料 4 財務摘要 5 業務摘要 7 管理層討論及分析 23 企業管治及其他資料 35 中期簡明綜合損益及其他全面收入表 36 中期簡明綜合財務狀況表 38 中期簡明綜合權益變動表 39 中期簡明綜合現金流量表 41 中期簡明綜合財務資料附註 57 定義 2025 年中期報告 2 執行董事： 吳豫生博士 （董事長兼總裁） 非執行董事： 李鈞博士 顧虹博士 蔣鳴昱博士 孟曉英博士 （於2025年8月31日辭任） 何超先生 朱向陽博士 （於2025年6月26日獲委任） 獨立非執行董事： 冷瑜婷博士 （主席） 吳豫生博士 張森泉先生 （於2025年9月15日辭任） 提名委員會 吳豫生博士 （主席） 張森泉先生 （於2025年9月15日辭任） 冷瑜婷博士 科學委員會 吳豫生博士 （主席） 李鈞博士 許文青博士 張森泉先生 （於2025年9月15日辭任） 冷瑜婷博士 許文青博士 沈秀華博士 監事 牛成山博士 梁阿朋博士 尚靜女士 審計委員會 張森泉先生 ...

Core Insights - The article highlights the changes in the stock holdings of various companies under the Hong Kong Stock Connect program, indicating significant increases and decreases in ownership percentages among different firms [1][2]. Group 1: Companies with Increased Holdings - Longpan Technology (02465) saw the largest increase in holdings, up by 4.42%, bringing its total to 51.59% [2]. - Tongyuan Kang Pharmaceutical-B (02410) experienced a 4.13% increase, resulting in a holding of 21.22% [2]. - Tianyue Advanced (02631) had a 4.11% increase, with a current holding of 11.33% [2]. - Other notable increases include: - Dazhong Public Utilities (01635): +1.71%, 34.70% [2] - Zhaoyan New Drug (06127): +1.63%, 45.73% [2] - Baize Medical (02609): +1.54%, 4.27% [2] Group 2: Companies with Decreased Holdings - Heng Seng China Enterprises (02828) experienced the largest decrease, down by 6.17%, now holding 0.68% [2]. - Yingfu Fund (02800) saw a reduction of 2.85%, with a holding of 1.77% [2]. - Shandong Molong (00568) decreased by 2.27%, now at 54.96% [2]. - Other significant decreases include: - China General Nuclear Power Corporation (01164): -1.18%, 15.65% [2] - Baiguoyuan Group (02411): -0.69%, 10.72% [2] Group 3: Five-Day Holding Changes - Over the last five trading days, Tongyuan Kang Pharmaceutical-B (02410) had the highest increase of 4.88%, reaching 21.22% [3]. - Longpan Technology (02465) increased by 4.48%, totaling 51.59% [3]. - Brainstorm Aurora-B (06681) rose by 4.25%, now at 4.87% [3]. - Other notable increases include: - Baize Medical (02609): +4.10%, 4.27% [3] - Zhaoyan New Drug (06127): +3.26%, 45.73% [3] Group 4: Twenty-Day Holding Changes - Over the past twenty days, Tongyuan Kang Pharmaceutical-B (02410) saw an increase of 11.90%, now holding 21.22% [4]. - Anjiu Food (02648) increased by 11.46%, reaching 22.65% [4]. - COSCO Shipping Energy (01138) rose by 11.24%, with a holding of 67.64% [4].

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 6 September 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", TYK Medicines, Inc (the "Company") is writing to remind you that the Company has adopted electronic dissemination of corpo ...